Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2022 | The use of RNA vaccines to promote CAR-T stimulation in solid tumors

Sebastian Kobold • 27 Sep 2022
ITOC 2022
General

Sebastian Kobold, MD, PhD, Ludwig-Maximilians-Universität München, Munich, Germany discusses the utilization of RNA vaccines to overcome the challenges associated with CAR-T cells in solid tumors. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sebastian Kobold

Engineering next-generation cellular therapies for solid tumors
16:51
Engineering next-generation cellular therapies for solid tumors
Eric Smith et al. • 24 Apr 2026
Beyond T cells: emerging immune cell therapies in cancer
2:22
Beyond T cells: emerging immune cell therapies in cancer
Sebastian Kobold • 11 Dec 2025
Unique safety challenges in modulating non-T cell compartments
2:43
Unique safety challenges in modulating non-T cell compartments
Sebastian Kobold • 11 Dec 2025
Emerging CAR-T and bispecific antibody strategies in solid tumors
3:03
Emerging CAR-T and bispecific antibody strategies in solid tumors
Sebastian Kobold • 11 Dec 2025

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals